Table 12Results of Manufacturer’s Scenario Analysis With Alternative Costing

FCTOFailure With Anti-TNF Therapy
Ustekinumab q.8.w.Ustekinumab q.12.w.Ustekinumab q.8.w.Ustekinumab q.12.w.
Base case$86,414$50,912$83,535$38,764
Free IV induction dose$78,638$42,827$73,835$25,152
Ustekinumab rebate
5%$75,336$41,428$77,256$31,571
10%$69,557$37,384$69,242$25,896
15%$63,777$33,339$61,229$20,222
20%$57,998$29,295$53,215$14,547
Annual per-patient expenditure caps
$20,000$40,543$40,943$29,014$30,890
$18,000$32,683$32,935$18,116$19,654
$16,000$24,823$23,656$7,217$6,637
$14,000$16,963$16,942DominatingDominating
Free cost of ustekinumab after re-initiating therapy after surgery$77,487$42,950$68,304$25,445

FCTO = failure with conventional therapy only; IV = intravenous; q.8.w. = every 8 weeks; q.12.w. = every 12 weeks; TNF = tumour necrosis factor.

Source: Manufacturer’s pharmacoeconomic submission.1

From: APPENDIX 3, REVIEWER WORKSHEETS

Cover of Ustekinumab (Stelara)
Ustekinumab (Stelara) [Internet].
Copyright © CADTH 2017.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.